Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma
2016
Abstract
We report a case of a female patient with stage IV melanoma treated with four doses of ipilimumab and a subsequent reinduction regimen, who responded to the therapy with a 5 year stable disease. During therapy, elevation of absolute lymphocyte count (ALC) and leukocytosis occurred, which was attributed to clinical response to ipilimumab.
Later, submandibular and cervical lymphadenopathy appeared, and a biopsy revealed B-cell CLL.